Evaluation of GW406381 for treatment of osteoarthritis of the knee: Two randomized, controlled studies

MedGenMed Medscape General Medicine

Volumn 10, Issue 11, 2008, Pages

  Boswell, Diane J ^a   Ostergaard, Keld ^c   Philipson, Richard S ^a   Hodge, Rachel A ^a   Blum, David ^b   Brown, Judith C ^a   Quessy, Steve N ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Clinical Research and Medical Affairs' BDS International   (United States)

^c Osteoarthritis Research Centre   (Denmark)

^d qd Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; GW 406381; PLACEBO; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FOOT EDEMA; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEART ARREST; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER ABDOMINAL PAIN; WEIGHT GAIN; AGED; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PYRAZOLES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 56749103761     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J. 2003;79:377-383.
2. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155.
3. Schaible HG, Ebersberger A, von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002;966:343-354.
4. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361:184-187.
5. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease; potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001;44:1237-1247.
6. Ebersberger A, Grubb BD, Willingale HL, et al. The intraspinal release of prostaglandin E2 in a model of acute arthritis is accompanied by an up-regulation of cyclo-oxygenase-2 in the spinal cord. Neuroscience. 1999;93:775-781.
7. De Leo JA, Tawfik VL, LaCroix-Fralish ML. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain. 2006;122:17-21.
8. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450-455.
9. Bajaj P, Bajaj P, Graven-Nielsen T, et al. Osteoarthritis and its association with muscle hyperalgesia: an experimental, controlled study. Pain. 2001;93:107-114.
10. Hendiani JA, Westlund KN, Lawand N, et al. Mechanical sensation and pain thresholds in patients with chronic arthropathies. J Pain. 2003;4:203-211.
11. Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotropic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain. 2000;88:69-78.
12. Beswick P, Bingham S, Bountra C, et al. Identification of 2,3-diaryl-pyrazolo [1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett. 2004;14:5445-5448.
13. Bingham S, Beswick P, Brown T, et al. GW406381X, a highly brain penetrant and potent cycloooxygenase (COX-2) inhibitor. Program and abstracts of the 11th World Congress on Pain; IASP 2005; Sydney, Australia.
14. Bingham S, Beswick PJ, Bountra C, et al. The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo [1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther. 2005;312:1161-1169.
15. Zhao FY, Spanswick D, Martindale JC, et al. GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. Pain. 2007;28:78-87.
16. Altman R, Asch E, Block D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039-1049.
17. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494-502.
18. Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498-502.
19. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840.
20. Kidd BL, Urban LA. Mechanisms of inflammatory pain. Br J Anaesth. 2001;87:3-11.
21. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil. 2004;12:389-399.
22. Collins R, Baigent C, Sandercock P, et al. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. BMJ. 1994;309:1215-1217.
23. Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford). 2002;41:1052-1061.
24. Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin. 2002;18:49-58
25. McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol. 2001;30:11-18.
26. Schnitzer TJ, Beier J, Geusens P, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;51:549-557.
27. Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res. 2001;29:467-479.
28. Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ. 2004;329:1317.
29. Sheldon E, Beaulieu A, Paster Z, et al. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther. 2005;27:64-77.
30. Tannenbaum H, Berenbaum F, Reginster JY, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: A 13 week, randomised double blind study versus placebo and celecoxib. Ann Rheum Dis. 2004;63:1419-1426.
31. Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee of hip osteoarthritis. Ann Rheum Dis. 2004;63:931-939.
32. Williams GW, Hubbard RC, Yu SS, et al. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther. 2001;23:213-227.
33. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
34. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289-300.
35. Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165:490-496.
36. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients Y65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
37. Creamer P, Hunt M, Dieppe P. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. J Rheumatol. 1996;23:1031-1036.